Effect of medication on biomechanical properties of rabbit bones: Heparin induced osteoporosis

Clinical Rheumatology

Volumn 16, Issue 6, 1997, Pages 585-595

  Akkas, Nuri ^e   Yeni, Y N ^a   Turan, B ^b   Delilbasi, E ^c   Gunel, U ^d  

^a West Virginia University   (United States)

^b ANKARA UNIVERSITY   (Turkey)

^c GAZI UNIVERSITY   (Turkey)

^d ANKARA NUMUNE HOSPITAL   (Turkey)

^e MIDDLE EAST TECHNICAL UNIVERSITY   (Turkey)

Author keywords

3 Point Bending; Calcitonin; Compression; Heparin; Osteoporosis; Tamoxifen

Indexed keywords

CALCITONIN; HEPARIN; TAMOXIFEN CITRATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOMECHANICS; BONE STRENGTH; BONE STRESS; COMPRESSIVE STRENGTH; CONTROLLED STUDY; DRUG EFFECT; DRUG INDUCED DISEASE; FEMALE; FEMUR; HEPARINIZATION; HUMERUS; INTRAPERITONEAL DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS; PRIORITY JOURNAL; RABBIT; STRESS STRAIN RELATIONSHIP; TIBIA;

EID: 0031397248     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02247799     Document Type: Article

References (62)

1. Albright F, Burnett CH, Cope O, Parson W. J Clin Endocrinol 1941; 1:711-16.
2. Krupp MA, Chatton MJ.Current medical diagnosis and treatment. Lange Medical Publications Los Altos, California, 1978.
3. Bockman RS, Weinerman SA. Steroid induced osteoporosis. The Orthop Clinics North Am 1990; 21(1):97-107.
4. Overgaard K, Riis BJ, Pudenphant J, Johansen JS. Nasal calcitonin for treatment of established osteoporosis. Clin Endocrinol 1989; 30: 435-42.
5. Kalu DN. Evolution of the pathogenesis of postmenopausal bone loss. Bone 1995; 17(4 Suppl): 135S-144S.
6. Boskey AL: Bone mineral and matrix. Are they altered in osteoporosis?. The Orthop Clin North Am 1990; 21(1): 19-29.
7. Kalu DN, Liu CC, Hardin RR, Hollis BW. The aged rat model of ovarian hormone deficiency bone loss. Endoc 1989;. 124: 7-16.
8. Wronski TJ, Yen CF, Burton KW, Mehta RC, Newman PS, Soltis EE, DeLuca PP. Skeletal effects of calcitonin in ovariectomized rats. Endocrinology 1991; 129(4): 2246-50.
9. Wronski TJ, Walsh CC, Ignaszewski LA. Histologic evidence for osteopenia and increased bone turnover in ovariectomized rats. Bone 1986; 7: 119-23.
10. Wronski TJ, Cintrón M, Dann LM. Temporal relationship between bone loss and increased bone turnover in ovariectomized rats. Calcified Tissue International 1988; 43: 179-83.
11. Hayashi T, Yamamuro T, Okumura H, Kasai R, Tada K. Effect of (Asu 1,7)-eel calcitonin on the prevention of osteoporosis induced by combination of immobilization and ovariectomy in the rat. Bone 1989; 10: 25-8.
12. Jordan VC, Phelps E, Lindgren JU. Effects of anti-estrogens on bone in castrated and intact female rats. Breast Cancer Research and Treatment 1987;10: 31-5.
13. Turner RT, Wakley GK, Hannon KS, Bell NH. Tamoxifen inihibits osteoclast-mediated resorption of trabecular bone in ovarian hormone-deficient rats. Endocrinology 1988; 122(3): 1146-50.
14. Mätzsch T, Bergqvist D, Hedner U, Nilsson B, Østergaard P. Effects of low molecular weight heparin and unfragmented heparin on induction of osteoporosis in rats. Thrombosis and Haemostasis 1990; 63(3): 505-9.
15. Ginsberg JS, Kowalchuk G, Hirsch J, Edwards PB, Burrows R, Coates G, Webber C: Heparin effect on bone density. Thrombosis and Haemostasis 1990; 64(2): 286-9.
16. Mätzsch T, Bergqvist D, Hedner U, Nilsson B, Østergaard P. Heparin-induced osteoporosis in rats. Thrombosis and Haemostasis 1986; 56 (3): 293-4.
17. Monreal M, Vinas L, Monreal L, Lavin S, Lafoz E, Angles AM. Heparin-related osteoporosis in rats; a comparative study between unfractioned heparin and a low-molecular-weight heparin, Haemostasis 1990; 20: 204-7.
18. Goulding A., Gold E., Effects of chronic prednisolone on bone resorption and bone composition in intact and ovariectomized rats and in ovariectomized rats receiving B-Estradiol. Endocrinol 1987; 122: 482-7.
19. Nicholson GC, Moseley JM, Yates AJP, Martin TJ. Control of cyclic adenosine 3,5-monophosphate production in osteoclasts: Calcitonin induced persistent activation and homologous desensitization of adenylate cyclase. Endocrinol 1987; 120: 1902-8.
20. Zhen M.H., Papadimitrious J.M., Nicholson G.C.: RNA synthesis in isolated rat osteoclasts: Inhibitory effect of calcitonin. Bone 1991; 122: 317-22.
21. Li BHP, Chiou GCY. Systemic administration of calcitonin through ocular route. Life Sciences 1992; 50 (5): 349-54.
22. Palmieri GMA, Pitcock JA, Brown P, Karas JG, Roen LJ. Effect of calcitonin and vitamin D in osteoporosis. Calcif Tissue Int 1989, 45: 137-41.
23. Mazzuoli GF, Passeri M, Gennari C, Minisola S, Antonelli R, Valtorta C, Palummeri E, Cervellin GF, Gonnelli S, Francini G. Effects of salmon calcitonin in postmenopausal osteoporosis: A controlled double-blind clinical study. Calcif Tissue Int 1989; 38: 3-8.
24. Goulding A., Gold E.: Estrogens and progestogens conserve bone in rats deficient in calcitonin and parathyroid hormone. Am J Physiol 257: E903-E908, 1989.
25. Torring O., Buch E., Sjostedy U., Stoberg H.E.: Salmon calcitonin treatment by nasal spray in primary hyperparothyroidium. Bone 1991; 12: 311-26.
26. Grubber HE, Ivey JL, Baylink DJ, Matthews M, Nelp WB, Sisom K, Chesnut CH. Long term calcitonin therapy in postmenopausal osteoporosis. Metabolism 1984; 33(4): 295-303.
27. Lerner UH, Ransjo M, Klaushofer K, Horandner H, Hoffman O, Czerwenka E, Koller K, Peterlik M. Comparison between the effects of forskolin and calcitonin on bone resorption and osteoclast morphology in vitro. Bone 1989; 10: 377-87.
28. Wright CDP, Evans WD, Mansell RE, Compston JE. The effect of long-term tamoxifen therapy on bone (Abstract). Clinical Science 1990; 79 (4): P30-P30.
29. Geusens P. Photon absorptiometry in osteoporosis: Bone mineral measurements in animal models and humans. Thesis for the degree of 'Geaggregeerde voor net Hoger Onderwijs', Katholieke Universiteit Leuven, 1992.
30. Van Audekercke R. The effect of osteoporosis on the mechanical properties of bone structures. Van der Perre G., Lowet G., Borgwardt Christensen A., ed. In vivo assesment of bone quality by vibration and wave propagation techniques, part III, Procedings of the COMAC-BME II.2.6 meeting, Toulouse, France, 1992.
31. Turner CH, Burr DB. Basic biomechanical measurements of bone: a tutorial. Bone 1993; 14: 595-608.
32. Baylink DJ, Wergedal JE, Farley JR, Einhorn TA. On fluoride and bone strength. Calcif Tissue Int 1995; 56(5): 415-8.
33. Katz JL, Yoon HS, Lipson S, Maharidge R, Meunier A, Christel P. The effects of remodeling on the elastic properties of bone. Calcified Tissue International 1984; 36: S31-S6.
34. Currey JD. The effect of porosity and mineral content on the Young's modulus of elasticity of compact bone. Journal of Biomechanics 1988; 21 (2): 131-9.
35. Schaffler MB, Burr DB. Stiffness of compact bone: Effects of porosity and density. Journal of Biomechanics 1988; 21 (1): 13-6.
36. Goh JCH, Ang EJ, Bose K. Effect of preservation medium on the mechanical properties of cat bones. Acta Orthop Scand 1989; 60(4): 465-7.
37. Beer FP, Johnston ER. Mechanics of materials, McGraw-Hill, Inc., 1987.
38. Yamada H. Strength of biological materials. Evans F. G., ed.The Williams and Wilkins Company, 1970.
39. Dowdy S, Wearden S. Statistics for research, John Wiley & Sons, Inc., New York, 1983.
40. Turan B, Delilbasi E, Sinav B, Akkas N. Zinc-calcium interaction in heparin-induced osteoporotic rabbit plasma. Trace Elements and Electrolytes 1996; 13: 138-42.
41. Sackler JP, Liu L. Heparin-induced osteoporosis. Br J Radiol 1973; 46: 548-50.
42. Griffiths HT, Liu DTY. Severe heparin osteoporosis in pregnancy. Postgrad Med J 1984; 60: 424-5.
43. Jaffe MD, Willis PW. Multiple fractures associated with long-term sodium heparin therapy. JAMA 1965; 193: 152-4.
44. Squires JW, Pinch LW. Heparin-induced spinal fractures. JAMA 1979; 241: 2417-8.
45. Griffith GC, Nichols G, Asher JD, Flanagan B. Heparin osteoporosis. JAMA 1965; 193: 85-8.
46. Ambrus JL Jr, Robin JC, Kelly RS, Mannley N, Thomas CC, Ambrus JL. Studies on osteoporosis. I. Experimental models. Effect of age, sex, genetic background, diet, steroid and heparin treatment on calcium metabolism of mice. Res Commun Chem Pathol Pharmacol 1978; 22: 3-14.
47. Melissari E, Murray WJG, Das S, Wilson NV, Philip M, Kakkar VV. Does low molecular weight heparin have a role in the development of osteoporosis? (Abstract). Thrombosis and Haemostasis 1993; 69(6): 646.
48. Levine M, Hirsh J. Non-hemorrhagic complications of anticoagulant therapy. Sem Thromb Hemostas 1986; 12(1): 63-5.
49. McDermott MT, Kidd GS. The role of calcitonin in the development and treatment of osteoporosis. Endocrine Reviews 1987; 8(4): 377-90.
50. Nishioka T, Kurayama H, Yasuda T, Udagawa J, Matsumura C, Niimi H. Nasal administration of salmon calcitonin for prevention of glucocorticoid-induced osteoporosis in children with nephrosis. The Journal of Pediatrics 1991; 118(5): 703-7.
51. Overgaard K, Hansen MA, Nielsen VH, Riis B, Christiansen C. Discontinuous calcitonin treatment of established osteoporosis-effects of withdrawal of treatment. The American Journal of Medicine 1990; 89: 1-6.
52. Overgaard K, Riis BJ, Christiansen C, Hansen MA. Effect of salcatonin given intranasally on early postmenopausal bone loss. BMJ 1989; 299: 477-9.
53. Civitelli R, Gonnelli S, Zacchei F, Bigazzi S, Vattimo A, Avioli LV, Gennari C. Bone turnover in postmenopausal osteoporosis; effect of calcitonin treatment. J Clin Invest 1988; 82: 1268-74.
54. Granata Q, Amato A, Salvati R., Barberis F. Activity of salmon calcitonin in senile osteoporosis. Current Therapeutic Research 1991; 49(5): 784-91.
55. Avioli LV. Heterogeneity of osteoporotic syndromes and the response to calcitonin therapy. Calcif Tissue Int 1991; 49 (Suppl 2): S16-S19.
56. Jordan VC, Fritz NF, Tormey DC.: Long-term adjuvant therapy with tamoxifen effects on sex hormone binding globulin and antithrombin III. Cancer Res 1987; 47: 4517-9.
57. Turner RT, Wakley GK, Hannon KS, et al: Tamoxifen prevents the skeletal effects of ovarian hormone deficiency in rats. J Bone Min Res 1987; 2: 449-56.
58. Moon LY, Wakley GK, Turner RT Dose-dependent effects of tamoxifen on long bones in growing rats: influence of ovarian status. Endocrinology 1991;129(3): 1568-74.
59. Love R. Tamoxifen therapy in primary breast cancer: biology, efficacy, and side effects. Journal of Clinical Oncology 1989; 7(6): 803-15.
60. Vincent J. Structural Biomaterials, Princeton University Press, 1990.
61. Zimran A, Shilo S, Fisher D, Bob I. Histomorphometric evaluation of reversible heparin induced osteoporosis in pregnancy. Arch Intern Med 1986; 146: 386-8.
62. Fornander T, Rutqvist LE, Sjöberg HE, Blomqvist L, Mattsson A, Glas U. Long-term adjuvant tamoxifen in early breast cancer: effect on bone mineral density in postmenopausal women. Journal of Clinical Oncology 1990; 8(6): 1019-24.